{"name":"Genascence Corporation","slug":"genascence-corporation","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTFBjdWlwSzktdFRaa2YwRF90ZjU2MDkxVDR5UTktdmpDN0h1YUVrbXZBMjdpMTR6cTlsZjUxMmxvRXBFNmxtSFpIbWFsRkM4Vlk4enZpTXpLamJtQzFaSFJBMEt0Y1g?oc=5","date":"2025-08-04","type":"pipeline","source":"The Pharma Letter","summary":"Genascence Corporation - The Pharma Letter","headline":"Genascence Corporation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgJBVV95cUxQaUhtY3JQQTBPeXpVUXI4bTBreWlHNGRnWVMtQ3BTcjhKU0VaMGpkLUl6N0pSWnNWeVdhYWpUa2tFemgxVzFrek9YTGd6bkpETTEtaVZFSWtTQ1BLT2tQb3R0ZUo1ell2ZUtvMm1LX2kxNl9vLTBGV1R1QmJ5Z0pVcnpGdVdobFptVmF1R0ZxaU1hWDUxdE5iaFN3Ml9XdlNwaHpfMzlPNExmRWhxaU10RHFqQzBWV3MyZzVmSmY1LTBWQldkMFBFSi1NNzl4TFZKTXBNNjNoeFRkd0REVmM4dkFJSGZGT0lpQjVkb1ZsYzlQS1U4RmlNUmNoQlViMkZqcWYtaXVtc1VMcEQyT1lncER3YU1oaDdKSkl3d1MwNjJtTmJjQkJFZGVReUxJVGliZUE?oc=5","date":"2025-07-16","type":"pipeline","source":"businesswire.com","summary":"Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC-001 for Knee Osteoarthritis (OA) - businesswire.com","headline":"Genascence Announces U.S. Food and Drug Administration Grants Regenerative Medicine Advanced Therapy Designation to GNSC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQSlZYRGlfc2t3SjZ4RFVtMm9ITDhRWU5DbjhuZFNOMlN3YURHd2JnTk1NODg4akI5QU1tb091VndkSV81Q2FpRkVfTzhncFR1NWpiS3lsdkZWUEd2YXFCb29BNk5UVTdHQ0NnZnIxbzdTWEdyeHFrWVBsVUlsVnE2NDM3aWcxRGRLV0Q4SGg0Z0RBSS1LVHZtQXpmU2tQdnpOc3pueUdROHR3UXBKamNJcmN5dkE?oc=5","date":"2025-02-04","type":"regulatory","source":"drugdiscoverytrends.com","summary":"The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root - drugdiscoverytrends.com","headline":"The FDA Fast-Tracked GNSC-001 gene therapy targets osteoarthritis at its root","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNZkR3dEV0TXhEZkhNYU5OaTd4NnQxbGJhMXBybFdGSDRFY1UwX05UdnM1SVdSWXkzSmdnRDJ2ZHhaTUFad0pwR3pIY0NRY2Y1cHFiOTVtbFlTZkR6cFZiUERTQVZtS0lJZHl6OTktTkdVOFhQT2tXODdjUktmVUU2bDJBa2hPUTZ0Z2FGeElYclQzT0FfSHN6alRNaFFYVUJZOWZCM1hfc1dyOURyVWJzbGNmQ2NxRTVhYnVtYjBsUXVTem0zM2VwX3NwY005aHNJQ1pYMnR5Vks5anNXQlVVM2FOeVVEMGdPYjdlSzVSNWNIa0pNX1ZsTTFXckdSNlJIZXFrTmVkSFN4X1VjRl9MX0xXd1FVZXF5Z1lGOVhzRy1FQks1aUtF?oc=5","date":"2025-01-09","type":"trial","source":"prnewswire.com","summary":"Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms - prnewswire.com","headline":"Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Acr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQdzZJN2M5OV82Z2VRdXFDVU9La0tiUk9jS2NFM004a01YTXg5dXN0MnVFeUZRMHhDSkpJRzZjWUczOFF2cnIzbm9JbW9iQVNQS0ZOTXAtOE9GQ25yUWt5RlVKVHVmWVZPckplVHRhbzBVSFVsdDQtZmN0SE1xcVdpU1dUeHVZZlF0Z1VSOWJOZEdGd3RCZkR4ekJDV1ZDWjlKd3FzdTZ3eUJwV3lhbHN2b1pyZlM?oc=5","date":"2024-10-29","type":"pipeline","source":"prnewswire.com","summary":"Genascence Appoints Jeymi Tambiah as Chief Medical Officer - prnewswire.com","headline":"Genascence Appoints Jeymi Tambiah as Chief Medical Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxOT3U5dzBSVXd2NGg2VDc2RG9TR1JJdnRONjlZb2ZGcFdhT1JVOXY5RlU5aFVCMlhrVXU0MVh2amNyYndTaTZXNXBXQUxfNkw1cUhQVlNQUC0xOGl3MXlNN2tKSF83Z0lQOHF3V24wZ280UmR5R3lOTUQ2UVVONXU5YzVZLWJORXpBUnFhTDhBY0h5cHBnWndqWTZHWUdldmNYUVVvbU9kY2VpMnFCN1dST0xn?oc=5","date":"2023-01-20","type":"pipeline","source":"drugdiscoverytrends.com","summary":"Genascence is betting on gene therapy for osteoarthritis - drugdiscoverytrends.com","headline":"Genascence is betting on gene therapy for osteoarthritis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPdTh2dDVUMHk2QjFjLUhGdmptWFBJZTlKdWxNWllFSUlST0VDMUJsVlNHb0hMT2ZTZjlxZ1BfUGRDTXpGbEdOby1JTDJkVDZESWpWYXBwRFJhd3BhYUZFeXZ6bU8zVm80MVF2bFE0bHJJWVVUSXRzTDFEWlpGZXpobFJrOHNLdXRlbGNQYkRJSDJUUGkyWmdCVDJtblpGX1dMcnRBdFVCZUxDU2E0a3NQM0wyV2t0X3ZUYjQtdF9kRDBQSi16UzJUMFNQdmc0dzhWUy1xWDBJQUFrMmJIWWw3azByVjVETzY3UHIwT1lmelowRkRpT0xLcXZB?oc=5","date":"2022-05-10","type":"pipeline","source":"BioSpace","summary":"Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scientific Advisory Board - BioSpace","headline":"Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Directors and Scie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigJBVV95cUxNMV85amtkRjBoQ0tOSTNvei1JYkhYdVo2anZGSjVtNUd0R24zTUZUTThKak1NSHFVOVh0dnlVNTJVQXNfR29tX1NacG9jSFZxS1FMZmk4Q2lSb09pRDBmbnc4NXE5QllmdHpnai13NUJfZjVlQUMwTkM5UFZKWDB3VjFDLVh2V29ab3pFOEd1b2ZWdXF1eGpqY2JvbGdhaHBQT3FfeEk0RHRRNVpMQVFTTjlSczVIOGs3UnJIUmpfWGtreXVVU1J2ZDdpSW5ZRmEyanVGQnBkdnY2T2hMQW5fN1lYcl9YMklfamRwTlBDQXBkeWtDWXpPbnVzMEJFekhnTFQxZjB4Zl9Pdw?oc=5","date":"2021-05-05","type":"trial","source":"prnewswire.com","summary":"Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthritis - prnewswire.com","headline":"Genascence Announces Completion of Dosing and Interim Safety Data for Phase 1 Clinical Trial of GNSC-001 in Osteoarthrit","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}